Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter endedJune 30, 2025and provided a corporate update. https://mma.prnewswire.com/media/627654/Lipocine_Logo.jpg Neuroactive Steroids — LPCN 1154 (oral brexanolone product candidate) is a non-invasive, 48-hour treatment option targeted for rapid symptom […]